Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Werewolf Therapeutics, Inc. HOWL announced that it has entered into a collaboration and supply agreement with pharma giant Merck MRK to evaluate its lead pipeline candidate, WTX-124, in combination ...

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report), Oric Pharmaceuticals (ORIC – Research Report) and Acadia ...

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of ...

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) is anticipated to issue its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce ...